Non-Allergic Asthma Risk and Your Genetics

By the ExomeDNA Research Team | Last reviewed: 2026-05-25

This page is for informational purposes only. For health decisions, consult a clinician.

Non-allergic asthma — also called intrinsic or non-atopic asthma — is a form of airway disease driven by inflammatory and structural changes in the airways that are triggered by non-immunological stimuli rather than allergens. Triggers such as cold air, exercise, respiratory viral infections, inhaled irritants, and occupational exposures characterize this asthma subtype. Unlike allergic asthma, it does not involve IgE-mediated sensitization to specific allergens, and blood IgE levels are typically normal.

What is non-allergic asthma?

Non-allergic asthma is characterized by airway hyperresponsiveness and airway remodeling — structural changes to the airway wall involving smooth muscle hypertrophy, goblet cell hyperplasia, and alterations in the extracellular matrix. The inflammatory profile differs from allergic asthma: rather than eosinophilic inflammation driven by Th2 immune responses, non-allergic asthma may involve neutrophilic inflammation, mixed inflammatory patterns, and activation of innate immune pathways.

This distinction has clinical implications: non-allergic asthma tends to be less responsive to inhaled corticosteroids than allergic asthma, is more common in adults, and is more frequently associated with obesity and other metabolic conditions. The genetic architecture of non-allergic asthma overlaps partially with allergic asthma but also includes distinct loci reflecting differences in immune and structural biology.

The genetics behind non-allergic asthma

Research into the genetic architecture of non-allergic asthma is still developing, and current evidence suggests a polygenic landscape spanning immune regulation, airway remodeling, and transcriptional control of inflammatory gene expression. Several genes in the associated locus set connect to specific aspects of intrinsic airway biology.

BACH2 — immune tolerance and regulatory T cell function

BACH2 encodes a transcription factor that plays a critical role in the differentiation of regulatory T cells (Tregs) and in suppressing inflammatory gene expression in lymphocytes. Research has associated BACH2 variants with a range of immune-mediated conditions — including type 1 diabetes, rheumatoid arthritis, and inflammatory bowel disease — as well as asthma. BACH2 restrains the expression of genes that drive Th2 and other inflammatory responses; when BACH2 function is reduced, immune tolerance may be impaired, potentially predisposing to airway inflammation. Some research has associated variants near BACH2 with asthma susceptibility including non-atopic subtypes.

ADAM19 — airway remodeling metalloprotease

ADAM19 (a disintegrin and metalloprotease domain 19) is a membrane-anchored enzyme involved in the ectodomain shedding of growth factors and cytokines, including TGF-β ligands and neuregulin. TGF-β is a central mediator of airway remodeling in asthma — driving smooth muscle hypertrophy and subepithelial fibrosis. Research has associated ADAM19 expression with airway remodeling and bronchial hyperresponsiveness in experimental models. Variants near ADAM19 may influence the degree of structural airway changes associated with non-allergic asthma.

CLEC16A — autophagy and antigen-presenting cell regulation

CLEC16A encodes a C-type lectin domain protein that regulates autophagy in immune cells, particularly dendritic cells and macrophages. Autophagy is essential for antigen processing and for clearing damaged cellular components. CLEC16A variants have been associated with multiple autoimmune and immune-mediated conditions, including type 1 diabetes, multiple sclerosis, and primary biliary cholangitis. In the context of non-allergic asthma, CLEC16A may modulate how innate immune cells in the airway respond to non-allergenic stimuli — a mechanism relevant to non-IgE-mediated airway inflammation.

CEBPA — transcription factor for neutrophil and granulocyte development

CEBPA encodes CCAAT/enhancer-binding protein alpha, a transcription factor essential for the development and function of neutrophils and other granulocytes. Non-allergic asthma, particularly the severe subtype, is often characterized by neutrophilic airway inflammation rather than the eosinophilic pattern typical of allergic asthma. Variants near CEBPA may influence the supply or activation state of neutrophils and other innate immune cells that contribute to non-allergic airway inflammation.

ACTN3 — airway smooth muscle and muscle mechanics

ACTN3 encodes alpha-actinin 3, a cytoskeletal protein highly expressed in fast-twitch skeletal muscle. The common R577X variant in ACTN3 — widely studied in the context of athletic performance — eliminates alpha-actinin 3 protein expression. Alpha-actinin proteins anchor actin filaments and are also expressed in smooth muscle. Airway smooth muscle contraction and tone are central to asthma pathophysiology. Research has associated ACTN3 variants with exercise-induced bronchoconstriction in some datasets, a form of airway hyperresponsiveness that may overlap with non-allergic triggers.

BRD2 — chromatin regulation of immune gene expression

BRD2 encodes bromodomain-containing protein 2, an epigenetic reader that binds acetylated histones and facilitates transcriptional elongation of inflammatory genes. Bromodomain proteins regulate the expression of cytokines, chemokines, and other immune mediators in response to inflammatory stimuli. Variants near BRD2 have been associated with immune-mediated conditions. In airway biology, BRD2-mediated transcriptional regulation may influence the gene expression profile of inflammatory cells in the asthmatic airway.

CARD11 — NF-κB signaling in lymphocytes

CARD11 encodes a scaffold protein that organizes the signaling complex linking antigen receptor activation to NF-κB — a transcription factor central to lymphocyte activation, cytokine production, and immune responses. Loss-of-function variants in CARD11 cause immunodeficiency, while gain-of-function variants cause inflammatory conditions. Common variants near CARD11 may modulate the threshold for lymphocyte activation, potentially influencing airway immune responses in non-allergic asthma.

COL16A1 — extracellular matrix and airway remodeling

COL16A1 encodes collagen type XVI alpha 1, a non-fibrillar collagen that participates in extracellular matrix organization. Airway remodeling in asthma involves structural alterations to the extracellular matrix beneath the airway epithelium, contributing to permanent changes in airway geometry and compliance. Variants near COL16A1 may influence the composition or stability of the airway matrix, affecting the extent of structural remodeling.

What the research says

Zhu et al. (2020) investigated shared genetic and experimental links between obesity-related traits and asthma subtypes in the UK Biobank, distinguishing between allergic and non-allergic asthma to identify subtype-specific loci. The study applied Mendelian randomization and GWAS analysis to assess whether genetic predisposition to obesity-related metabolic states contributes to non-allergic asthma susceptibility. Some research has associated genetic variants near immune regulation and airway remodeling genes — including BACH2, ADAM19, and CLEC16A — with non-allergic asthma risk, though effect sizes for individual loci are modest and replication across datasets varies.

Shared obesity-asthma genetic architecture Zhu et al. (2020) found evidence for shared genetic factors between obesity-related traits and non-allergic asthma in the UK Biobank, suggesting that metabolic and inflammatory pathways may connect these conditions beyond simple epidemiological association.^[¹]

Distinct genetic loci for asthma subtypes Research has identified partially distinct genetic architectures for allergic and non-allergic asthma subtypes, with loci near immune regulation genes such as BACH2 and CLEC16A more strongly associated with non-allergic presentations — consistent with the innate immune and neutrophilic biology of intrinsic asthma.^[¹]

Research base: Moderate.

How non-allergic asthma risk affects you

Higher genetic susceptibility to non-allergic asthma reflects a modest increase in population-level risk rather than a deterministic outcome. Non-allergic asthma is common — affecting a substantial proportion of adult asthma cases — and its development depends on the interaction of genetic predisposition with environmental exposures, respiratory infections, obesity, occupational hazards, and other factors.

From a genetic perspective, variants near BACH2, CLEC16A, and CEBPA suggest that immune regulatory pathways — particularly those governing neutrophilic and innate immune airway responses — are key contributors to non-allergic susceptibility. Variants near ADAM19 and COL16A1 implicate airway structural remodeling as an additional axis of genetic influence.

For individuals with existing asthma, the distinction between allergic and non-allergic subtypes influences management: non-allergic asthma may respond less robustly to inhaled corticosteroids, and identifying specific triggers is particularly important. A pulmonologist or allergist can guide subtype classification and appropriate treatment selection.

Working with your asthma risk profile

Environmental and lifestyle factors substantially modify non-allergic asthma risk and outcomes. Research has associated the following with lower asthma risk or better asthma control: avoiding smoking (including secondhand smoke), managing body weight (given the obesity-asthma genetic connection), reducing exposure to occupational respiratory irritants, and managing viral respiratory infections through vaccination and general hygiene measures.

For individuals with asthma, key non-allergic triggers to identify and manage include cold air (often manageable with a scarf or face covering during exercise), high-intensity exercise (pre-treatment with a short-acting bronchodilator if recommended by a clinician), strong chemical odors, and respiratory infections that can destabilize asthma control.

Pharmacological management of non-allergic asthma typically includes inhaled corticosteroids, long-acting bronchodilators, and short-acting rescue bronchodilators. Biologic therapies targeting IL-5 or IL-4/IL-13 pathways may be less effective in non-eosinophilic, non-allergic asthma; newer biologics targeting TSLP or IL-33 may be relevant. A specialist can guide therapy selection based on asthma phenotype and inflammatory markers.

Related traits and genes

• Allergic Asthma — the IgE-mediated subtype; shares some genetic loci with non-allergic asthma but also has distinct architecture
• Chronic Obstructive Pulmonary Disease (COPD) — shares airway remodeling biology; distinct triggers and mechanism but overlapping structural changes
• Hay Fever / Allergic Rhinitis — a related allergic condition; less genetically correlated with non-allergic asthma than with allergic asthma
• Obesity — shares genetic architecture with non-allergic asthma through metabolic-inflammatory pathways

Frequently asked questions

What distinguishes non-allergic asthma from allergic asthma?

Allergic (atopic) asthma is triggered by allergen exposure and involves IgE-mediated sensitization, eosinophilic airway inflammation, and elevated total and allergen-specific IgE. Non-allergic asthma is triggered by non-immunological stimuli — cold air, exercise, irritants, viral infections — and is not associated with elevated IgE or allergen sensitization. The inflammatory profile tends toward neutrophilic rather than eosinophilic, and treatment responses differ accordingly.

Why does BACH2 appear in non-allergic asthma genetics?

BACH2 is a transcription factor critical for immune tolerance, particularly through its role in regulatory T cell differentiation and suppression of inflammatory gene expression in lymphocytes. Some research has associated BACH2 variants with a range of immune-mediated diseases. In non-allergic asthma, reduced BACH2 function may impair immune tolerance in the airway, allowing innate inflammatory responses to non-allergenic stimuli to be more easily triggered.

Is non-allergic asthma related to obesity?

Research has found both epidemiological and genetic links between obesity and non-allergic asthma. Mechanistic pathways likely include metabolic inflammation (adipokines and systemic inflammation affecting airway biology), mechanical effects of excess weight on lung function, and shared genetic factors influencing both conditions. Managing body weight has been associated with improved asthma control in individuals with obesity-related non-allergic asthma.

What triggers non-allergic asthma?

Common triggers for non-allergic asthma include cold air, vigorous exercise, strong chemical odors or fumes, respiratory viral infections, nonsteroidal anti-inflammatory drugs (in some individuals), occupational dust and chemical exposures, and psychological stress. Identifying personal triggers through diary-keeping and discussion with a clinician is an important step in managing non-allergic asthma.

How is non-allergic asthma treated?

Treatment of non-allergic asthma typically follows the same step-care approach as allergic asthma, starting with inhaled corticosteroids and short-acting bronchodilators, with addition of long-acting bronchodilators for moderate-to-severe cases. Biologic therapies are less clearly effective in non-allergic, non-eosinophilic asthma. Trigger avoidance and management of contributing factors such as body weight and occupational exposures are particularly important in this subtype. A pulmonologist or allergist can advise on appropriate management.

This page is for informational purposes only and is not a clinical determination, treatment recommendation, or clinical genetic test.